Keyphrases
Adjuvant Therapy
100%
Combination Chemotherapy
100%
Paclitaxel
100%
Carboplatin
100%
Papillary Serous
100%
Chemotherapy Regimen
100%
Serous Cell
100%
Endometrial Clear Cell Carcinoma
100%
Uterine Serous Carcinoma
75%
Uterine Clear Cell Carcinoma
75%
In(III)
50%
Treatment Cessation
25%
Chemotherapy
25%
Delayed Diagnosis
25%
Adjuvant Chemotherapy
25%
Retrospective Analysis
25%
Neutropenia
25%
Anemia
25%
No Evidence of Disease
25%
Median Survival
25%
Highly Aggressive
25%
Obstetrics
25%
Advanced Stage
25%
Area under the Curve
25%
Disease Status
25%
Endometrial Cancer
25%
Stage III-IV
25%
Toxicity Profile
25%
Neuropathy
25%
Dose Reduction
25%
Anaphylaxis
25%
Treatment Delay
25%
Optimal Debulking
25%
Pelvic Radiotherapy
25%
Aggressive Variant
25%
International Federations
25%
6-cycles
25%
Chemotherapy Schedule
25%
Progression-free Interval
25%
Medicine and Dentistry
Endometrial Cancer
100%
Adjuvant Therapy
100%
Paclitaxel
100%
Carboplatin
100%
Clear Cell
100%
Chemotherapy Regimens
100%
Clear Cell Carcinoma
75%
Endometrium Carcinoma
75%
Disease
50%
Neutropenia
25%
Recurrent Disease
25%
Anemia
25%
Obstetrics
25%
Neuropathy
25%
Debulking
25%
Therapy Delay
25%
Progression Free Survival
25%
Adjuvant Chemotherapy
25%
Gynecology
25%
Anaphylaxis
25%
Drug Dose Reduction
25%
Pelvic Radiotherapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Paclitaxel
100%
Endometrium Cancer
100%
Carboplatin
100%
Chemotherapy Regimens
100%
Chemotherapy
75%
Clear Cell Carcinoma
75%
Endometrium Carcinoma
75%
Disease
50%
Recurrent Disease
25%
Anemia
25%
Progression Free Survival
25%
Neuropathy
25%
Neutropenia
25%
Anaphylaxis
25%